Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

OREXIGEN THERAPEUTICS

SummaryNewsCompany 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Orexigen Therapeutics, Inc. : Orexigen Announces Successful Interim Analysis of Contrave Light Study

11/25/2013 | 08:13am EST

SAN DIEGO, Nov. 25, 2013 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced successful results of the interim analysis of the Light Study. Based on these results, the Company will resubmit the Contrave® New Drug Application (NDA) to the United States Food and Drug Administration (FDA) in the next few weeks with potential approval by June 2014. 

"The interim analysis of the Light Study clearly achieved the goal set by the FDA," said Michael Narachi, CEO of Orexigen.  "The resubmission will contain an unprecedented amount of cardiovascular outcomes data for an obesity therapeutic, and we are confident these data will support a favorable benefit:risk assessment for Contrave."

The FDA previously agreed that if the interim analysis meets the specified criteria to exclude cardiovascular risk, Contrave could be approved. The pre-specified criteria for the interim analysis is to exclude a hazard ratio of 2.0, using the upper bound of the 95% confidence interval, for excess risk of major adverse cardiovascular events (MACE) in patients receiving Contrave as compared to placebo. In addition to meeting the pre-specified criteria for excluding cardiovascular risk, no new safety signals were observed.

"Takeda is excited about this major milestone for Contrave," said Doug Cole, President of Takeda Pharmaceuticals U.S.A., Inc., Orexigen's partner for Contrave in North America. "Takeda is pleased to partner with Orexigen to develop a therapeutic option that has the potential to help patients achieve meaningful and sustained weight loss over time."

Conference Call This Morning at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time)

The Orexigen management team will host a teleconference and webcast to discuss the interim analysis results. The live call may be accessed by phone by calling (888) 895-5479 (domestic) or (847) 619-6250 (international), participant code 36202424. The webcast can be accessed live on the Investor Relations section of the Orexigen web site at www.orexigen.com and will be archived for 14 days following the call.

About the Light Study

The Contrave Light Study is a double


© Publicnow 2013
All news about OREXIGEN THERAPEUTICS
2018OREXIGEN THERAPEUTICS : Enters Agreement for Sale of Company
PU
2016OREXIGEN THERAPEUTICS : Announces Stockholder Approval of All Proposals at 2016 Annual Mee..
PU
2016OREXIGEN THERAPEUTICS : Analysts View on Drug Manufacturers - Other Equities - Endo Intl.,..
PR
2016OREXIGEN THERAPEUTICS : Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR
2016OREXIGEN THERAPEUTICS : Announces Promotions of Tom Cannell to COO and Jason Keyes to CFO
PR
2016OREXIGEN THERAPEUTICS : Reports Favorable Markman Ruling in Contrave® Patent Litigation
PR
2016OREXIGEN THERAPEUTICS : Announces Upcoming Presentations at European Obesity Summit 2016
PR
2016OREXIGEN THERAPEUTICS : Founder and Former Chairman Eckard Weber Steps Down from Board
PR
2016OREXIGEN THERAPEUTICS : Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR
2016OREXIGEN THERAPEUTICS : Appoints New Member of Board of Directors and Announces Senior Man..
PR
More news
Sector and Competitors
1st jan.Capi. (M$)
OREXIGEN THERAPEUTICS0
GILEAD SCIENCES, INC.-1.16%90 027
REGENERON PHARMACEUTICALS-2.58%64 327
VERTEX PHARMACEUTICALS6.58%59 510
WUXI APPTEC CO., LTD.-3.73%52 722
BIONTECH SE-23.97%47 338